JNJ logo

Johnson & Johnson (JNJ)

$278.70

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on JNJ

Market cap

$670.92B

EPS

6.58

P/E ratio

30.3

Price to sales

6.43

Dividend yield

1.923%

Beta

0.219933

Price on JNJ

Previous close

$282.55

Today's open

$278.99

Day's range

$277.56 - $281.72

52 week range

$195.90 - $290.25

Profile about JNJ

CEO

Joaquin Duato

Employees

140800

Headquarters

New Brunswick, NJ

Exchange

New York Stock Exchange

Shares outstanding

2.41B

Issue type

Common Stock

JNJ industries and sectors

Healthcare

Pharmaceuticals

News on JNJ

Here's How Much Passive Income $50,000 Generates in These 4 Dividend Aristocrats

Four household-name stocks have raised their dividends for 40 to 70 straight years, yet each one carries a risk that could threaten the streak. Which payout looks safest, and which check is biggest?

news source

24/7 Wall Street • 7 hours ago

news preview

Invest $25,000 in These 4 Dividend Stocks to Start Building Retirement Income

Retirement changes what a portfolio is for. Once the paycheck stops, the number that matters most is how much cash the account sends back each year without pushing a sale of shares.

news source

24/7 Wall Street • 4 hours ago

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

news source

GlobeNewsWire • a day ago

news preview

J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition

JNJ's $2.2 billion Ollin acquisition adds a phase III eye disease candidate to its pipeline, with Blackstone providing $750 million to fund the development.

news source

Zacks Investment Research • Nov 17, 2026

news preview

J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts

J&J's $2.2 billion Ollin Biosciences deal adds a promising retinal disease candidate, building on acquisitions.

news source

Zacks Investment Research • Nov 17, 2026

news preview

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

news source

Zacks Investment Research • Nov 17, 2026

news preview

Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

news source

Zacks Investment Research • Nov 17, 2026

news preview

Louisiana Appeals Court Upholds Millions in Damages in Mesothelioma Case Against Johnson & Johnson

DALLAS--(BUSINESS WIRE)--An appeals court in Louisiana has upheld a multimillion verdict against Johnson & Johnson, in which a jury found that talc in its baby powder caused a New Orlean's woman's mesothelioma and death.In a Nov. 16 ruling, Louisiana's Fourth Circuit Court of Appeal affirmed a trial court's decision to increase damages awarded to the family of Jeannine Henderson. National plaintiffs trial firm Dean Omar Branham Shirley, LLP (DOBS) represented the Henderson family as well as.

news source

Business Wire • Nov 17, 2026

news preview

3 Bulletproof Passive Income Dividend Kings to Buy and Hold Forever

A pending IRS ruling, rising commodity costs, and more test whether the payouts of these passive income Dividend Kings can survive.

news source

24/7 Wall Street • Nov 17, 2026

news preview

Forget SCHD: 4 Dividend Stocks Retirees Should Own Instead

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) grounds countless retirement portfolios. SCHD screens for durable dividend payers, holds $112.3 billion in net assets and pays a trailing yield near 2.94%.

news source

24/7 Wall Street • Nov 17, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Johnson & Johnson

Open an M1 investment account to buy and sell Johnson & Johnson commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in JNJ on M1